Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Inc.

Citi analyst Geoff Meacham maintained a Buy rating on Regeneron today and set a price target of $900.00. According to TipRanks, Meacham is a 5-star...

Citi Reaffirms Their Buy Rating on Regeneron (REGN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN), Bausch + Lomb Corporation (BLCO) and Indivior (...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Bausch + Lomb Corporation (BLCO) and Indivior (INDV)

Here’s a quick look at today’s key earnings reports from major publicly traded companies. Investors will be watching closely for updates on financi...

These Are the Stocks Reporting Earnings Today – April 29, 2026

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGX) and Regeneron (REGN) with bullish s...

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Regeneron (REGN)

In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Regeneron, with a price target of $801.00. Renza covers ...

Truist Financial Sticks to Their Buy Rating for Regeneron (REGN)

In a report released today, Louise Chen from Scotiabank maintained a Hold rating on Regeneron, with a price target of $770.00. According to TipRank...

Scotiabank Sticks to Their Hold Rating for Regeneron (REGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK) and Regeneron (REGN) with bull...

Analysts’ Top Healthcare Picks: Merck & Company (MRK), Regeneron (REGN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Jade Biosciences (JBIO), Elevance Health (ELV) and...

Analysts Conflicted on These Healthcare Names: Jade Biosciences (JBIO), Elevance Health (ELV) and Regeneron (REGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and Regeneron (REGN) with ...

Market Cap	$61.26B	P/E Ratio	19.49
52W High	$821.11	52W Low	$476.49
Div Yield	376.0%	Payout Ratio	8.2%
EPS Growth 3Y	2.1%	52W Position	65.3%
Overall Score	62	Value Score	80
Quality Score	57	Technical Score	50

EPS Current Est	$35.98	EPS Next Est	$42.14
EPS Growth Est	+17.1%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REGN	$701.42	-0.80%	728.88K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REGN	$701.42	-0.8%	728.88K
3
4
5
6

REGN

REGN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Regeneron Pharmaceuticals Inc. Data in Excel

Get Regeneron Pharmaceuticals Inc. Data in Excel